Aura Biosciences grants SVP 23,540 RSUs, options
Amy Elazzouzi received new awards, including 23,540 RSUs and a 46,460-share option, with option vesting starting Oct. 1, 2026 and RSUs first vesting Sept. 15, 2027.
Rhea-AI Filing Summary
Aura Biosciences, Inc. (AURA) reported that officer Amy Elazzouzi, SVP, Finance & PAO, received new equity awards. On 2026-09-01 she was granted 23,540 RSUs, each representing one share of common stock upon vesting, bringing her directly held common shares to 143,600. The RSUs vest in four substantially equal annual installments, with the first tranche vesting on September 15, 2027, subject to continued service. She was also granted a stock option for 46,460 shares of common stock at an exercise price of $7.43 per share, vesting as to 1/48th of the award monthly starting October 1, 2026, and expiring on September 1, 2036, also subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 70,000 shares
Grant/Award
2 txns
Insider
Elazzouzi Amy
Role
SVP, Finance & PAO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F2 | 46,460 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 23,540 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 46,460 contracts (Direct);
Common Stock — 143,600 shares (Direct)
Footnotes (2)
- F1. The reported transaction represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock upon vesting and settlement. These RSUs shall vest in four substantially equal annual installments, subject to the Reporting Person's continued service to the Issuer on each vesting date, with the first tranche vesting on September 15, 2027.
- F2. The stock option shall vest as to 1/48th of the total award monthly, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 1, 2026.
Key Figures
RSUs granted: 23,540 shares
Common shares following RSU grant: 143,600 shares
Stock option grant size: 46,460 shares
+4 more
7 metrics
RSUs granted
23,540 shares
Restricted stock units granted on 2026-09-01 under 2021 Stock Option and Incentive Plan
Common shares following RSU grant
143,600 shares
Directly held Aura Biosciences common stock after the 23,540-share RSU award
Stock option grant size
46,460 shares
Stock Option (Right to Buy) granted on 2026-09-01
Stock option exercise price
$7.43 per share
Exercise price for 46,460-share stock option granted to Amy Elazzouzi
RSU first vesting date
September 15, 2027
First tranche of four substantially equal annual RSU installments
Option vesting commencement
October 1, 2026
Stock option vests as to 1/48th of the award monthly starting on this date
Option expiration date
September 1, 2036
Expiration of the 46,460-share stock option grant
Key Terms
restricted stock units ("RSUs"), 2021 Stock Option and Incentive Plan, vesting, Stock Option (Right to Buy)
4 terms
restricted stock units ("RSUs") financial
"The reported transaction represents a grant of restricted stock units ("RSUs") under"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2021 Stock Option and Incentive Plan financial
"grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan"
vesting financial
"These RSUs shall vest in four substantially equal annual installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
FAQ
What equity awards did AURA grant to Amy Elazzouzi on September 1, 2026?
On 2026-09-01, Amy Elazzouzi received 23,540 RSUs and a stock option for 46,460 shares of Aura Biosciences common stock at an exercise price of $7.43 per share, both subject to service-based vesting conditions.
How do the 23,540 RSUs granted by AURA to Amy Elazzouzi vest?
The 23,540 RSUs vest in four substantially equal annual installments, subject to Amy Elazzouzi’s continued service, with the first tranche vesting on September 15, 2027. Each RSU represents the right to receive one share of Aura Biosciences common stock upon vesting and settlement.
What are the key terms of Amy Elazzouzi’s new stock option from AURA?
The stock option covers 46,460 shares of Aura Biosciences common stock with an exercise price of $7.43 per share, vesting as to 1/48th of the total award monthly starting October 1, 2026, and expiring on September 1, 2036, subject to continued service.
Under which plan did AURA grant RSUs to Amy Elazzouzi?
The 23,540 RSUs granted to Amy Elazzouzi were issued under Aura Biosciences’ 2021 Stock Option and Incentive Plan. Each RSU entitles her to receive one share of common stock upon vesting and settlement, subject to continued service-based vesting conditions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
